| Literature DB >> 29367653 |
.
Abstract
Radiomics is one such "big data" approach that applies advanced image refining/data characterization algorithms to generate imaging features that can quantitatively classify tumor phenotypes in a non-invasive manner. We hypothesize that certain textural features of oropharyngeal cancer (OPC) primary tumors will have statistically significant correlations to patient outcomes such as local control. Patients from an IRB-approved database dispositioned to (chemo)radiotherapy for locally advanced OPC were included in this retrospective series. Pretreatment contrast CT scans were extracted and radiomics-based analysis of gross tumor volume of the primary disease (GTVp) were performed using imaging biomarker explorer (IBEX) software that runs in Matlab platform. Data set was randomly divided into a training dataset and test and tuning holdback dataset. Machine learning methods were applied to yield a radiomic signature consisting of features with minimal overlap and maximum prognostic significance. The radiomic signature was adapted to discriminate patients, in concordance with other key clinical prognosticators. 465 patients were available for analysis. A signature composed of 2 radiomic features from pre-therapy imaging was derived, based on the Intensity Direct and Neighbor Intensity Difference methods. Analysis of resultant groupings showed robust discrimination of recurrence probability and Kaplan-Meier-estimated local control rate (LCR) differences between "favorable" and "unfavorable" clusters were noted.Entities:
Mesh:
Year: 2018 PMID: 29367653 PMCID: PMC5784146 DOI: 10.1038/s41598-017-14687-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographics, disease and treatment characteristics for the three subsets.
| Characteristics | Training set n (%) | Tuning set n (%) | Test set n (%) | All 3 sets combined n (%) |
|---|---|---|---|---|
|
| ||||
|
| 229 (89.8) | 131 (79.4) | 40 (88.9) | 400 (86) |
|
| 26 (10.2) | 34 (20.6) | 5 (11.1) | 65 (14) |
| Age at diagnosis, years: median (range) | 57 (28–83) | 59.2 (29.5–88.5) | 58 (43–89) | 58 (28–89) |
|
| ||||
|
| 240 (94.1) | 145 (87.9) | 42 (93.3) | 427 (91.8) |
|
| 5[ | 9 (5.5) | 2 (4.5) | 16 (3.4) |
|
| 9 (3.6) | 8 (4.8) | 1 (2.2) | 18 (4) |
|
| 1 (0.3) | 0 (0) | 0 (0) | 1 (0.2) |
|
| 0 (0) | 3 (1.8) | 0 (0) | 3 (0.6) |
|
| ||||
|
| 83 (32.5) | 67 (40.6) | 19 (42.2) | 169 (36.3) |
|
| 54 (21.2) | 40 (24.2) | 11 (24.5) | 105 (22.6) |
|
| 118 (46.3) | 58 (35.2) | 15 (33.3) | 191 (41.1) |
|
| ||||
|
| 122 (47.8) | 85 (51.5) | 25 (55.6) | 232 (49.9) |
|
| 123 (48.2) | 79 (47.9) | 19 (42.2) | 221 (47.5) |
|
| 8 (3.1) | 0 (0) | 0 (0) | 8 (1.7) |
|
| 2 (0.8) | 1 (0.6) | 0 (0) | 3 (0.7) |
|
| 0 (0) | 0 (0) | 1 (2.2) | 1 (0.2) |
|
| ||||
|
| 141 (55.3) | 83 (50.3) | 24 (53.3) | 248 (53.3) |
|
| 106 (41.6) | 59 (35.8) | 17 (37.9) | 182 (39.1) |
|
| 3 (1.2) | 3 (1.8) | 2 (4.4) | 8 (1.7) |
|
| 3 (1.2) | 0 (0) | 1 (2.2) | 4 (0.9) |
|
| 2 (0.8) | 0 (0) | 0 (0) | 2 (0.4) |
|
| 0 (0) | 8 (4.8) | 0 (0) | 8 (1.7) |
|
| 0 (0) | 2 (1.2) | 0 (0) | 2 (0.4) |
|
| 0 (0) | 10 (6.1) | 1 (2.2) | 11 (2.5) |
|
| ||||
|
| 36 (14.2) | 53 (32.1) | 3 (6.7) | 92 (19.8) |
|
| 114 (44.7) | 65 (39.4) | 21 (46.7) | 200 (43) |
|
| 67 (26.3) | 28 (17) | 11 (24.4) | 106 (22.8) |
|
| 38 (14.9) | 19 (11.5) | 10 (22.2) | 67 (14.4) |
|
| ||||
|
| 15 (5.9) | 20 (12.1) | 5 (11.1) | 40 (8.6) |
|
| 13 (5.1) | 28 (17) | 5 (11.1) | 46 (9.9) |
|
| 220 (86.3) | 113 (68.5) | 31 (69) | 364 (78.3) |
|
| 7 (2.7) | 4 (2.4) | 2 (4.4) | 13 (2.8) |
| Nx | 0 (0) | 0 (0) | 2 (4.4) | 2 (0.4) |
|
| ||||
|
| 0 (0) | 3 (1.8) | 0 (0) | 3 (0.6) |
|
| 4 (1.6) | 8 (4.8) | 3 (6.7) | 15 (3.2) |
|
| 21 (8.2) | 35 (21.2) | 6 (13.3) | 62 (13.3) |
|
| 230 (90.2) | 119 (72.1) | 56 (80) | 385 (82.9) |
|
| ||||
|
| 103 (40.3) | 128 (77.6) | 6 (13.3) | 237 (51) |
|
| 11 (4.3) | 37 (22.4) | 3 (6.7) | 51 (11) |
|
| 141 (55.3) | 0 (0) | 36 (80) | 177 (38) |
|
| ||||
|
| 2 (0.8) | 40 (24.2) | 9 (20) | 51 (11) |
|
| 45 (17.6) | 4 (2.4) | 3 (6.7) | 52 (11.2) |
|
| 127 (49.8) | 96 (58.2) | 27 (60) | 250 (53.8) |
|
| 81 (31.8) | 25 (15.2) | 6 (13.3) | 12 (24) |
|
| ||||
|
| 65 (25.5) | 27 (16.4) | 8 (17.8) | 100 (21.5) |
|
| 190 (74.5) | 138 (83.6) | 37 (82.2) | 365 (78.5) |
| Radiation dose[ | 70 Gy | 70 Gy | 70 | 70 Gy |
| Radiation fractions (median) | 33 | 33 | 33 | 33 |
|
| ||||
|
| 226 (88.6) | 136 (82.4) | 29 (64.4) | 391 (84.1) |
|
| 29 (11.4) | 29 (17.6) | 16 (35.6) | 74 (15.9) |
|
| ||||
|
| 237 (92.9) | 154 (93.3) | 41 (91.1) | 432 (92.9) |
|
| 18 (7.1) | 11 (6.7) | 4 (8.9) | 33 (7.1) |
| Time to local failure, median (range) | 56 (1–101) | 50.9 (1.8–137) | 58 (1–117) | 54.9 (1–137) |
Figure 1‘Actual Martingale residual’ by ‘predicted value from random forest’ plot of time-to-local failure for the three sets based on the radiomic signature.
Figure 2Local tumor control by permutations of radiomics-based image features combination. Kaplan-Meier curve showing local control (in months) for patients classified against different values. (Intensity Direct LRM = Intensity Direct Local Range Max, NID2.5 Complexity = Neighbor Intensity Difference 2.5 Complexity) We give the number of subjects at 0, 12, 24, 36, 48 and 60 months follow-up who were still at risk (i.e., not censored or been diagnosed with local failure or died). 2(a) Training set (n = 255). 2(b) Tuning set (n = 165). 2(c) Test set (n = 45) (Note that the two upper lines in this curve are overlapping given the absence of events, i.e. local failure in this permutation).
Wald Test (DF = degree of freedom).
| Source | Number of parameters | DF | Wald ChiSquare | Prob > ChiSq |
|---|---|---|---|---|
| Combination radiomic signature | 2 | 2 | 13.187 | 0.001* |
| HPV Status | 2 | 2 | 6.337 | 0.042* |
| Smoking status | 2 | 2 | 5.820 | 0.055 |
| Age | 1 | 1 | 4.379 | 0.036* |
| Sex | 1 | 1 | 0.193 | 0.661 |
| Therapeutic Combination | 3 | 3 | 2.910 | 0.406 |
| T | 3 | 3 | 0.165 | 0.983 |
| N | 4 | 4 | 0.592 | 0.964 |
Effect Likelihood Ratio Tests (L-R = Likelihood ratio).
| Source | Number of parameters | DF | L-R ChiSquare | Prob > ChiSq |
|---|---|---|---|---|
| Combination radiomic signature | 2 | 2 | 17.826 | 0.0001* |
| HPV Status | 2 | 2 | 7.334 | 0.026* |
| Smoking status | 2 | 2 | 7.289 | 0.026* |
| Age | 1 | 1 | 4.973 | 0.026* |
| Sex | 1 | 1 | 0.191 | 0.662 |
| Therapeutic Combination | 3 | 3 | 8.363 | 0.039* |
| T | 3 | 3 | 0.166 | 0.983 |
| N | 4 | 4 | 2.5801 | 0.630 |
Effect summary in the light of False Discovery Rate (FDR) test.
| Source | FDR LogWorth | FDR P Value | |
|---|---|---|---|
| Combination radiomic signature | 3.312 |
| 0.0004 |
| Smoking status | 1.334 |
| 0.046 |
| Age | 1.011 |
| 0.098 |
| Therapeutic Combination | 0.985 | 0.103 |
Figure 3Flowchart of patient selection for inclusion.